Ondansetron
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-ONDANSETRON |
|---|---|
| Type | Drug |
| Aliases | ZofranОндансетрон |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-AML |
| Sources | SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | 5-HT3 receptor antagonist (antiemetic) |
|---|---|
| Mechanism | Selective 5-HT3 receptor antagonist; blocks vagal stimulation of vomiting reflex. |
| Typical dosing | 8-16 mg IV/PO before chemotherapy + q8h × 24-48h |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Standard antiemetic premedication for moderately/highly emetogenic chemotherapy (e.g., bendamustine).
Used By
Regimens
REG-CINV-4DRUG-HEC- 4-drug CINV prophylaxis (high-emetogenic chemo: NK1 + 5HT3 + dex + olanzapine)
Supportive Care
SUP-ANTIEMETIC-PREMED- Antiemetic premedication for moderately emetogenic chemotherapy